Dilon Technologies Announces the Beginning of Enrollment in its Pivotal Trial of the Next Generation MarginProbe™ 2 Used in Real-Time Margin Assessment

First Patient Enrollment

Dilon Technologies Inc. announced today the enrollment of its first patient in the Prospective, Single-Arm, Multi-Center Pivotal Trial for its next generation MarginProbe 2 product used in real-time margin assessment.

Dr. Mehran Habibi, MD

“It is thrilling to witness the development and launch of the MarginProbe 2 study. Being actively involved in advancing real-time margin assessment technology remains a significant and ongoing commitment for me,” stated Dr. Mehran Habibi, MD, who is the Chief of Breast Surgery of the Western Region of Northwell Health in NY and Director of the Breast Program at Staten Island University Hospital. Dilon Technologies has 5 (five) US hospital sites approved and ready to begin enrolling patients. “I have already experienced great results with the current MarginProbe technology. Being a part of the trial for a next generation MarginProbe 2 that may yield a higher sensitivity may reduce the number of false negatives and help us do even better for our patients,” stated Dr. Lori Alfonse, DO, Deputy Physician-in-Chief at the Lehigh Valley Health Network Cancer Institute based in Allentown, PA.

Learning Group Data

In the learning group, sensitivity in the MarginProbe 2 ranged between 75% – >90% sensitivity. Dilon has not seen other technology showing publicly available data with comparable sensitivity rates. “I’ve already been able to bring re-excision rates down to 4.5% using the current MarginProbe in my practice. Participating in a trial for the next generation device is extremely exciting to hopefully improve upon that,” said Dr. Vincent Reid, MD, breast surgeon from Mercy Medical Center in Iowa.

Moving Forward

Dilon Technologies looks to continue building evidence around its MarginProbe platform that already has over 12 peer-reviewed publications demonstrating reduction in re-excision rates. “We remain committed to being a leader in women’s healthcare by providing technology for patients that will improve their outcomes. MarginProbe is beginning to become an integral component of breast surgery for more surgeons across the United States each month,” stated George Makhoul, CEO of Dilon Technologies.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.
AppliedVR Co-founder and President Josh Sackman, "We're committed to developing a significant body of scientific evidence that demonstrates how our RelieVRx program, which is rooted in self-regulation, cognitive behavioral therapy skills and mindfulness, engages the brain and can impact the experience of pain. While we know there can be a strong placebo effect, this feasibility study showed that only the active RelieVRx treatment created changes at a physiological and brain activity level, creating a strong foundation for future research."
Researchers and clinicians from Emory Winship Cancer Institute collaborated to test their prostate cancer population notes Prevencio.
First patients treated with H-Guard at the National Institute for Health and Care Research Manchester Clinical Research Facility. MHRA approves continuation of Invizius's first-in-human clinical study following a prearranged two-patient safety and performance review. Study is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysis.

By using this website you agree to accept Medical Device News Magazine Privacy Policy